Austin-based molecular diagnostic company, Asuragen, Inc., made a presentation at the Association for Molecular Pathology’s (AMP) Annual Meeting on Genomic Medicine last week, which ran from Wednesday, Nov. 13, until Saturday, Nov. 16 in Phoenix, Arizona.
Two researchers from the company were invited to the meeting in order to facilitate a dynamic workshop on quantitative studies of BCR-ABL1 fusion transcripts, hosted by Asuragen. Both Dr. Douglas Smith from Johns Hopkins University and Dr. Lawrence Jennings from Northwestern University, gave in-depth talks on International Scale standardization with regard to tracking therapeutic responses in chronic myeloid leukemia cases.
The company’s advancements were also showcased to the event’s attendees through poster presentations about next generation sequencing (NGS). Researched data on NGS focused on the effect of rigorous pre-analytical DNA quality assessment criteria. A press release for the event stated that data from the studies presented demonstrate ” . . . the advantages of a novel PCR assay, QFI™-PCR, in quantifying functional DNA compared to fluorometry or spectrophotometry, and illustrates how this assay can guide corrections in FFPE DNA input to rescue low quality samples, improve the accuracy of variant detection, and minimize the burden of mutation confirmation.”
Asuragen used its workshop and presentations at the event to highlight its own AmplideX technology, which offers unprecedented sensitivity in detecting genetic fragile X mutations, as highlighted in a BioNews Texas article by Contributing Editor Charles Moore. At this year’s Annual Meeting, Asuragen presented novel data on the performance of AmplideX® in combination with low-cost electrophoresis platforms, with this new presentation expanding on more than 20 peer-reviewed publications that have previously demonstrated the utility of the AmplideX® FMR1 PCR Reagents for extensive molecular characterization of the fragile X gene.
In addition to the AmplideX-focused presentation, Asuragen also presented ” . . . a study describing a simplified PCR-only workflow for FMR1 methylation analysis evaluated by two European laboratories will be reported. The approach standardizes fragile X testing schemes without the need for Southern blot analysis, is compatible with alternative sample types to blood, and identifies low abundant mosaic alleles implicated in fragile X diagnosis and treatment.”